[Possibilities of correction of rheological properties of the blood and free radical processess in patients with acute myocardial infarction combined with type 2 diabetes mellitus].
Aim of the study was assessment of rheological parameters of the blood and processes of free radical oxidation as well as rate of arrhythmia development in patients with acute myocardial infarction (AMI) and type 2 diabetes mellitus (DM) whose otherwise standard therapy was supplemented with 90% omega-3 polyunsaturated fatty acid (PFA). We examined 63 patients with AMI and concomitant diabetes. 90% omega-3 PFA was given to 16 of these patients. Control group consisted of 22 practically healthy patients. Investigation of blood rheological parameters included measurement of viscosity of whole blood, determination of aggregation and morphofunctional structure of erythrocytes. Free radical processes were assessed by total amount of nitrates and nitrites in blood plasma, concentration of citrulline and malone dialdehyde. In patients with AMI taking its course at the background of type 2 DM compared with control group we observed changes of rheological properties of blood and processes of free radical oxidation which led to lowering of tissue oxygen supply. Standard therapy of AMI in more than 50% of patients did not result in adequate correction of impaired rheological parameters of blood. Addition of 90% omega-3 PFA to standard treatment of AMI was associated with improvement of aggregation and cytoarchitectonics of erythrocytes, lowering of activity of free radical oxidation, and by the end of 2nd week of treatment--with lessening of number of ventricular disturbances of cardiac rhythm. Thus supplementation of standard therapy with preparation 90% omega-3 PFA in patients with AMI and type 2 DM facilitates improvement of rheological properties of blood and processes of free radical oxidation, and prevention of arrhythmia.
Kudriashova
M V
MV
Dovgaliuk
Iu V
IuV
Mishina
L E
LE
Berezin
M V
MV
Grineva
M R
MR
Pakhrova
O A
OA
Mazanko
O E
OE
D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001809:Blood Viscosity; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D004562:Electrocardiography; D015716:Electrocardiography, Ambulatory; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005609:Free Radicals / Q000097:blood; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D009566:Nitrates / Q000097:blood; D009573:Nitrites / Q000097:blood; D012212:Rheology
D015525:Fatty Acids, Omega-3; D005609:Free Radicals; D009566:Nitrates; D009573:Nitrites